ALPCO Announces the Commercial Launch of its FDA 510(k) Cleared Calprotectin Immunoturbidimetric Assay
This innovative assay showcases a clinical sensitivity of 90.5% and a clinical specificity of 93.4%
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
21 Dec 23
This innovative assay showcases a clinical sensitivity of 90.5% and a clinical specificity of 93.4%
20 Dec 23
Both firms will develop MSI-H diagnostics for four types of cancer including endometrial, gastric, small intestinal, and biliary…
20 Dec 23
The Calprotectin Immunoturbidimetric Assay is authorised in the US for in vitro diagnostic use to diagnose inflammatory bowel…
20 Dec 23
LTS has also received funding from the Bill & Melinda Gates Foundation to support new formulation methods for…
20 Dec 23
The term of the distribution agreement with Verrue is 5 years and NuGen estimates sales to be approximately…
20 Dec 23
With technology becoming a key differentiator in providing quality healthcare, the medical device testing facility is designed to…
19 Dec 23
The collaboration aims to transform breast cancer imaging with the installation of 20 advanced Koning Vera Breast CT…
19 Dec 23
The collaboration has resulted in a clinical feasibility trial of GRIP Molecular Technologies’ patented electronic biosensor technology which…
19 Dec 23
Tyber Medical LLC, is a leading orthopedic device manufacturer providing rapid access to FDA-cleared and CE-marked private label,…
19 Dec 23
LUMA Vision will use the new funds to gain FDA clearance, prepare for U.S. commercialization and develop the…